ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   


By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Aegerion Pharmaceuticals, Inc. 

101 Main Street
Suite 1850
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-500-7867 Fax: 908-541-1155


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





 Company News
Aegerion Pharmaceuticals, Inc. (AEGR) Initiates Phase 3 Clinical Trial In Japan To Evaluate Lomitapide For Treatment Of Homozygous Familial Hypercholesterolemia (Hofh) 4/9/2014 8:23:40 AM    More...
Aegerion Pharmaceuticals, Inc. (AEGR) Grants Stock Options Under Inducement Program 4/8/2014 7:44:56 AM    More...
Aegerion Pharmaceuticals, Inc. (AEGR) Warns Of Negative Impact Of DOJ Investigation 3/6/2014 8:13:10 AM    More...
Aegerion Pharmaceuticals, Inc. (AEGR) Observes Rare Disease Day 2/28/2014 10:00:41 AM    More...
Aegerion Pharmaceuticals, Inc. (AEGR) Announces Presentation At The Cowen And Company Healthcare Conference 2/28/2014 9:37:42 AM    More...
Aegerion Pharmaceuticals, Inc. (AEGR) Announces Fourth-Quarter And Full-Year 2013 Financial Results 2/26/2014 9:12:38 AM    More...
Aegerion Pharmaceuticals, Inc. (AEGR) To Announce Fourth-Quarter And Full-Year 2013 Financial Results On Wednesday, February 26 2/13/2014 9:27:34 AM    More...
Aegerion Pharmaceuticals, Inc. (AEGR)' JUXTAPID(™) (Lomitapide) Capsules Approved In Canada For The Treatment Of Homozygous Familial Hypercholesterolemia (Hofh) 2/11/2014 7:11:55 AM    More...
Aegerion Pharmaceuticals, Inc. (AEGR) Grants Stock Options Under Inducement Program 2/10/2014 9:14:09 AM    More...
Aegerion Pharmaceuticals, Inc. (AEGR)'s JUXTAPID™ (Lomitapide) Capsules Approved In Canada For The Treatment Of Homozygous Familial Hypercholesterolemia (Hofh) 2/10/2014 7:17:29 AM    More...
12345678910...